Stocksigma LogoStocksigma Logo

Alembic Expands Strategic DifGen Tie-Up for US Complex Generics

Alembic Pharmaceuticals expanded its strategic collaboration with DifGen Pharmaceuticals to commercialize a portfolio of 20+ differentiated complex

Alembic Expands Strategic DifGen Tie-Up for US Complex Generics

Alembic Pharmaceuticals Ltd 路 Press Release 路 04 Nov 2026, 8:10 pm

Alembic Expands Strategic DifGen Tie-Up for US Complex Generics Alembic Pharmaceuticals expanded its strategic collaboration with DifGen Pharmaceuticals to commercialize a portfolio of 20+ differentiated complex generics in the US, targeting an aggregate reference market of ~$5 billion across injectable, transdermal, ophthalmic, and oral dosage forms. DifGen will manage development, regulatory, and US manufacturing, while Alembic will handle US commercialization and select manufacturing. The pipeline includes open First-to-File (FTF) assets and potential Day-1 launches with limited competition. Initial commercial launches are slated to commence from FY28, granting Alembic reserved US manufacturing capacity.

Original exchange filing (PDF)

More announcements from Alembic Pharmaceuticals Ltd

All Alembic Pharmaceuticals Ltd announcements